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Objective: Resident macrophages play an important role in atheromatous plaque rupture. The macro-
phage gene expression signature associated with plaque rupture is incompletely deﬁned due to the
complex cellular heterogeneity in the plaque. We aimed to characterise differential gene expression in
resident plaque macrophages from ruptured and stable human atheromatous lesions.
Methods and results: We performed genome-wide expression analyses of isolated macrophage-rich
regions of stable and ruptured human atherosclerotic plaques. Plaques present in carotid endarterec-
tomy specimens were designated as stable or ruptured using clinical, radiological and histopathological
criteria. Macrophage-rich regions were excised from 5 ruptured and 6 stable plaques by laser micro-
dissection. Transcriptional proﬁling was performed using Affymetrix microarrays. The proﬁles were
characteristic of activated macrophages. At a false discovery rate of 10%, 914 genes were differentially
expressed between stable and ruptured plaques. The ﬁndings were conﬁrmed in fourteen further stable
and ruptured samples for a subset of eleven genes with the highest expression differences (p < 0.05).
Pathway analysis revealed that components of the PPAR/Adipocytokine signaling pathway were the most
signiﬁcantly upregulated in ruptured compared to stable plaques (p ¼ 5.4  107). Two key components
of the pathway, fatty-acid binding-protein 4 (FABP4) and leptin, showed nine-fold (p ¼ 0.0086) and ﬁve-
fold (p ¼ 0.0012) greater expression respectively in macrophages from ruptured plaques.
Conclusions: We found differences in gene expression signatures between macrophages isolated from
stable and ruptured human atheromatous plaques. Our ﬁndings indicate the involvement of FABP4 and
leptin in the progression of atherosclerosis and plaque rupture, and suggest that down-regulation of
PPAR/adipocytokine signaling within plaques may have therapeutic potential.
 2012 Elsevier Ireland Ltd. Open access under CC BY license.1. Introduction
Atheromatous plaque erosion and rupture leading to athero-
thrombotic occlusion or distal embolisation is responsible for the
majority of the acute morbidity and mortality of atherosclerosis,
such asmyocardial infarction, unstable angina and thromboembolic
stroke [1]. Differences in cellular composition between stable and
ruptured plaques are well established. The macrophage is central to
the local inﬂammatory and apoptotic processes leading to plaque
instability and rupture, however, the molecular pathways in
macrophages that contribute to plaque rupture are incompletelyx: þ44 191 241 8666.
er CC BY license.characterized. The presence and character of differences in gene-
expression patterns between macrophages in stable and ruptured
lesions could identify metabolic and regulatory pathways that
inﬂuence plaque instability and rupture. Many previous gene
expression studies in human samples have comparedwhole plaques
with normal tissue, while fewer have compared gene expression
between stable and ruptured plaques [2e10]. The use of whole
plaques for gene expression analysis effectively pools the RNA of
various cell types in the plaque relative to their abundance, adding
a potentially confounding variable to the analysis. A cell-speciﬁc
approach has the potential to address the question of gene expres-
sion differences between particular cell types in stable and
unstable plaques with greater precision than approaches based on
the studyofwhole plaques.Using lasermicro-dissection,we isolated
total RNA from macrophage-rich regions of stable and ruptured
human atheromatous plaques derived from carotid endarterectomy
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radiological and histological criteria, and carried out genome-wide
gene expression proﬁling using microarrays.2. Materials and methods
2.1. Specimens
Carotid endarterectomy specimens were obtained from patients
undergoing surgery for symptomatic or asymptomatic carotid
stenoses at the Regional Neurosurgical Centre, Newcastle-upon-
Tyne. Magnetic resonance imaging (MRI) of the brain and 3D
gadolinium-DTPA contrast-enhanced magnetic resonance angiog-
raphy (MRA) of the carotid arteries were performed on a 1.5 T
scanner (Intera, Philips Medical Systems). Specimens were snap-
frozen in liquid nitrogen in the operating theatre immediately
upon removal. A portion of each specimen was sent for histo-
pathological analysis, and classiﬁed by two independent observers
(KL and TP) according to the Virmani scheme [1]. Informed consent
was obtained from all patients and Local Research Ethics
Committee approval was granted for this study.
We selected contrasting ruptured and stable samples for RNA
analysis. The criteria for ruptured samples comprised all three of
the following: symptoms consistent with stroke or transient
ischaemic event (TIA) within the last 3 months; signiﬁcant irreg-
ularities of plaque surface on 3DMRA (deﬁned as depressions in the
plaque surface of at least 2 mm); and histology of a Ruptured Thin
Fibrous Cap Atheroma with thrombus present. Conversely, the
criteria for stable samples were: no symptoms attributable to CVA/
TIA at any time; a smooth plaque surface morphology on 3D MRA
and no evidence of cerebral infarction on MRI; and histology of
a thick Fibrous Cap Atheroma or Fibro-Calciﬁc Plaque.2.2. Laser micro-dissection (LMD) and microarray analysis
Cryosections of 10 mm thickness were mounted on RNase-free
treated Leica thermoplastic membrane slides, then ﬁxed in 75%
ethanol, stained with haematoxylin, dehydrated in increasing
gradients of ethanol and rendered RNA stable for laser micro-
dissection. At every 10 sections, 3 additional ‘scout’ sections were
stained with haematoxylin and eosin to identify anatomical
features; these sections were immuno-stained using antibodies to
smooth muscle actin (Dako, 1A4, 1:400) to identify regions rich in
vascular smooth muscle cells, and CD68 (Dako, PG-M1, 1:125) to
identify regions rich in macrophages, using the Vectastain Elite ABC
Kit. These sections were used to guide laser micro-dissection of
macrophage-rich regions performed on the Leica AS LMD instru-
ment. Macrophage-rich CD68þ regions underlying thick ﬁbrous
caps and overlying atheromatous cores of stable lesions, and
macrophage-rich CD68þ regions underlying thin ﬁbrous caps,
overlying atheromatous cores and adjacent to the defect/rupture of
unstable lesions were microdissected. Cellularly mixed regions
containing both macrophage and SMCs were avoided.
RNA was isolated using the Qiagen RNeasy Micro kit. RNA
quality and quantity were assessed by RIN score using the RNA6000
Pico Labchip (Agilent Bioanalyser 2100, Agilent). Only samples with
RIN scores of 6 and above were considered suitable for microarray
analysis. For microarray analyses, 20e60 ng of total RNA were
subjected to two cycles of linear ampliﬁcation using the
Affymetrix GeneChip Two-Cycle Target Labeling Kit and hybrid-
ized to Affymetrix U133plus2 chips. Five ruptured and six stable
samples underwent microarray analysis. To replicate the results of
the microarray analysis for the most signiﬁcantly differentially
expressed genes, an additional seven stable and seven rupturedsamples underwent laser microdissection, and RNA extraction and
quality assessment, using the same protocol.
2.3. Quantitative PCR
The most signiﬁcantly differentially expressed genes from the
microarray experiment were conﬁrmed using qPCR both in the
samples from the microarray experiment and the replication set.
Unampliﬁed total-RNAwas reverse transcribed to cDNA by random
hexamer primers using the SuperScript3 First Strand Synthesis
System for RTPCR (Invitrogen). Quantitative real-time PCR was
performed using Taqman Gene Expression Assay primer-probes
with Taqman Universal PCR Master Mix on the ABI 7900HT
platform (Applied Biosystems). Expression levels of succinate
dehydrogenase complex subunit-A (SDHA) and peptydylprolyl
isomerase-A (PPIA) were used as references. These 2 control genes
were selected and validated from 7 candidate genes (details in
Supplemental materials). The analysis was performed using the
relative quantitation method with PCR efﬁciency corrections on
QBase [11].
2.4. Immunohistochemistry
Sections of 5 mm thickness from formalin-ﬁxed parafﬁn-
embedded carotid atheromatous plaque were immunostained with
anti-leptin mouse monoclonal antibodies (ABCAM, BDI142, 1:500)
and anti-fatty-acid binding-protein 4 (FABP4) rabbit polyclonal
antibodies (ABCAM, 1:150) using the Vectastain Elite ABC Kit and
visualized using Di-Amino Benzidine, to conﬁrm the expression
domains of Leptin and FABP4.
2.5. Statistical analysis
The microarray expression proﬁles were analysed using the
GeneSpring GX 7.3.1 analysis package. Raw microarray signal data
were pre-processed and normalized using GCRMA. Probesets that
were called absent in more than 6 of the 11 samples were excluded
from subsequent analyses. To conﬁrm that our LMD protocol had
successfully isolated RNA from macrophage-rich regions, we
compared the microarray data with expression proﬁles from the
NCBI Gene Expression Omnibus (GEO) repository (www.ncbi.nlm.
nih.gov/geo/). These included data from a panel of 79 different
cell and tissue types [12] (n ¼ 158), from adipocytes [13] (n ¼ 24)
and from 4 separate macrophage experiments [14e17] (n ¼ 106).
Relationships were visualized by Condition Tree clustering (using
Spearman correlation, as the similarity measure and conﬁdence
levels were assessed using 100 bootstraps), and Principal Compo-
nent Analysis (PCA). Additionally, a list of genes differentially
expressed during macrophage activation was obtained from the
paper by Cho et al. (3815 genes) [14]. The expression proﬁles of the
micro-dissected specimens for this subset of genes were compared
with repository samples of blood cell origin as well as activated and
unactivated macrophages.
Differentially expressed probesets were identiﬁed using ANOVA.
We made allowance for multiple testing using the false discovery
rate [18], adopting a threshold FDR of 10%. The BiNGO plug-in
(Biological Network Gene Ontology tool) for the open-source Java
platform Cytoscape [19] was used to identify signiﬁcantly over-
represented Gene Ontology Biological Processes among the differ-
entially expressed genes. We used WebGestalt [20] (WEB-based
Gene SeT AnaLysis Toolkit) to identify among the pathways in the
Kyoto Encyclopedia of Genes and Genomes (KEGG) database those
that were signiﬁcantly over-represented among the set of differ-
entially expressed genes. The signiﬁcance of over-representation
was calculated using the hypergeometric test.
Table 1
Demographics of patients included in unstable and stable sample groups and the
corresponding signiﬁcance between groups (SD e standard deviation, IQR e inter-
quartile range, ns e not signiﬁcant, yrs e years).
Unstable Stable p-value
No of samples (males) 12 (8) 13 (9) ns
Mean age (SD) 65.9 yrs (8.3) 66.2 yrs (8.0) ns
Median time from
last event (IQR)
42 days (30e180) n/a e
Mean maximal luminal
diameter stenosis on
MR angiogram (SD)
82.3% (11.1) 85.2%(12.8) ns
Smoking (present or previous) 67% 62% ns
Hypercholesterolemia 83% 100% ns
Hypertension 83% 69% ns
Diabetes 25% 23% ns
Ischemic heart disease 8% 54% 0.002
Medication: aspirin/clopidogrel 100% 92% ns
Medication: statin 83% 100% ns
Medication: ACEi/ARB 67% 69% ns
Medication: metformin 17% 23% ns
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3.1. LMD yielded cells with macrophage gene expression proﬁle
The demographics of the 25 patients included in the study
(twelve ruptured and thirteen stable samples) are shown in Table 1.
Examples of ‘scout’ sections stained with CD68 to identify
macrophage-rich regions for LMD and adjacent laser micro-
dissected cryosections are shown in Supplementary Fig. S1. The
quality of RNA extracted from the specimens was high; a repre-
sentative electropherogram of the extracted RNA is shown in the
Supplementary Fig. S2. Comparison of the microarray gene
expression signatures of the micro-dissected cells to the expression
proﬁles of various cell and tissue types by condition tree analysis
showed a close relationship between the micro-dissected cells and
macrophage cell-lines with a 99% bootstrap conﬁdence level
(Fig. 1). Importantly, the analysis showed only distant relationships
to the proﬁles of other cell types present in the vessel wall,
including smoothmuscle cells and T-lymphocytes, with a bootstrap
conﬁdence level of 100%. The principal components analyses
comparing only the expression of genes involved in macrophage
activation also showed that the gene expression proﬁles of the
micro-dissected samples were characteristic of activated macro-
phages (Supplemental Fig. S3).Fig. 1. Condition tree dendrogram demonstrating the correlation of the genomic expressi
(n ¼ 299) using Spearman correlation of the whole array genome-wide gene expression da3.2. Differences in gene expression proﬁles between stable and
ruptured plaques
Explorative clustering on the entire dataset using condition tree
and principal components analysis showed clustering of the 11
samples into 2 identiﬁable groups (Fig. 2). These groups corre-
sponded to their clinical designations as stable or ruptured plaques,
demonstrating that there were speciﬁc differences in the macro-
phage gene expression proﬁles between the 2 groups.We identiﬁed
914 genes (represented by 1187 probesets) that were signiﬁcantly
differentially expressed in stable and ruptured plaques at an FDR of
0.10. Fig. 2 shows the heatmap together with a list of the twenty
genes showing the highest differences in fold change between
stable and ruptured samples. A list of the 1187 signiﬁcantly up- and
down-regulated probesets in the microarray analysis is available in
the Supplemental materials. The complete MIAME-compliant
microarray dataset is available on GEO (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc¼GSE41571). Real-time quantitative PCR
assays of the 12 statistically signiﬁcant genes with the highest fold
change, using the unampliﬁed total-RNA from micro-dissection,
showed that the correlation between expression levels deter-
mined from microarray (linear-ampliﬁed) and from real-time PCR
(unampliﬁed) was high (Pearson r¼ 0.92), suggesting no signiﬁcant
artefact had been introduced by the two rounds of linear ampliﬁ-
cation necessary to generate sufﬁcient input material for micro-
array analyses from the small amounts of RNA obtained from LMD.
Expression of these 12 genes was assessed in additional 14 samples,
selected and processed in an identical fashion, by real-time PCR. In
the combined set of 25 samples (12 ruptured and 13 stable) there
was signiﬁcant evidence of differential expression (at p < 0.05) for
11 out of the 12 genes tested (Fig. 3). These results are broadly in
accordance with the FDR of 10% that we speciﬁed in the analyses of
the microarray data. Principal Components Analysis using the real-
time PCR data based on the expression of these 12 genes revealed
a separation of the 25 samples along an “axis of instability-stability”
in gene expression space (Fig. 3) that corresponded to clinical
presentation. Samples from patients who had had multiple events
clustered at one extreme and samples from patients who were
asymptomatic clustered at the other.
3.3. Pathway analysis
The most signiﬁcant Gene Ontology Biological Processes repre-
sented in the dataset were cell signaling (with sub-categories- cellon proﬁles of the 11 laser micro-dissected samples to other samples of various types
ta with bootstrap conﬁdence levels.
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156 genes, p ¼ 3.6  105) and cell adhesion (with 61 genes,
p ¼ 8.1  1011). Ten KEGG pathways were signiﬁcantly differen-
tially expressed at p < 0.001 (Supplementary Table S4). Seven of
these pathways were chieﬂy up-regulated in stable samples, two
had a balanced conﬁguration, and one, the PPAR/adipocytokine
signaling pathway, was chieﬂy up-regulated in ruptured when
compared to stable samples (p ¼ 5.4  107). The PPAR/adipocy-
tokine pathway was the fourth most signiﬁcantly differentially
expressed KEGG pathway, after Focal Adhesion (p ¼ 1.3  1010),
Adherens Junction (p ¼ 1.4  1010), and Actin Cytoskeleton
(p ¼ 2.6  109) pathways, which were more highly expressed in
stable samples. Fifteen differentially expressed genes were present
in the PPAR/adipocytokine signaling pathway, of which 11 were up-
regulated in the ruptured samples (Supplementary Table S5). FABP4Fig. 2. Unsupervised explorative clustering on the entire array datasets of the samples usin
group cluster closely together; the stable group, although clearly separate from the ruptur
geneous group). In panel C, statistically signiﬁcant differentially expressed genes (1187 pro
a heatmap is shown. Red represents over-expression, green represents under-expression. T
above 1 represents higher relative expression in the ruptured group and values below 1
references to colour in this ﬁgure legend, the reader is referred to the web version of thisand Leptin are key genes in the PPAR/adipocytokine signaling
pathway; these genes were conﬁrmed by real-time PCR amongst
the most differentially expressed statistically signiﬁcant genes in
the ruptured plaques compared to the stable plaques (FABP4: 9.3
fold over-expressed, p ¼ 0.009; Leptin: 5.5 fold over-expressed;
p ¼ 0.001; Fig. 3).
3.4. Immunohistochemistry of leptin and FABP4
We carried out immunohistochemical analyses of the proteins
encoded by leptin and FABP4 genes to conﬁrm the expression of
these genes in plaque macrophages in sixteen of the samples.
Leptin and FABP4 staining were present and co-localised to CD68
positive macrophage regions, and were absent from the smooth
muscle cell areas (Fig. 4).g condition tree (Panel A) and principal components analysis (Panel B). The ruptured
ed group, has a greater spread (as might be expected in a histologically more hetero-
besets representing 914 different genes) ranked by fold difference and represented in
he top 10 differentially expressed genes from both ends are listed. Fold change values
represents higher relative expression in the stable group. (For interpretation of the
article.)
Fig. 3. Panel A shows the real-time qPCR results of the 12 most signiﬁcantly differentially expressed genes tested in 12 ruptured and 13 stable specimens. The fold difference with
the 95% conﬁdence intervals and the ANOVA p-values are shown. Panel B shows the relative clustering and separation of the 25 samples in gene expression space using principal
components analysis on all the genes tested in RTqPCR.
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This study has demonstrated signiﬁcant differences in the gene
expression proﬁles betweenmacrophage-rich regions derived from
stable and ruptured atheromatous plaques. Comparison with
publicly available expression proﬁles from a variety of cell types
showed a close correspondence between our samples and activated
macrophages, indicating that we had largely been successful in
isolating macrophage-speciﬁc RNA. Leptin and FABP4, which both
have functions linking lipid metabolism to inﬂammation, were
among the most differentially expressed individual genes. More-
over, the adipocytokine/PPAR signaling pathway incorporating
both FABP4 and leptin was the most strongly up-regulated KEGG
pathway in ruptured samples (p ¼ 5.5  107). This is the ﬁrst
report of the involvement of the adipocytokine/PPAR signaling
pathway in plaque rupture. These cell-speciﬁc data from clinical
samples show the importance of genes in the pathway linking lipid
metabolism to inﬂammation in plaque instability, and conﬁrm the
data from mouse models suggesting that modifying the expressionor action of these genes in plaque macrophages may have thera-
peutic potential.
The majority of previous studies quantifying gene expression in
human atherosclerosis using microarrays and other approaches
have compared atheromatous with normal vessels (reviewed in
Bijnens et al. ATVB 2006 [2,3]). While such comparisons are clearly
of interest, they are not speciﬁc for the stage in the disease process
that causes the majority of the acute morbidity and mortality of
atherosclerosis, that is, plaque rupture. Fewer studies have been
conducted on whole stable and unstable/ruptured plaques [4e10].
While this approach should yield greater speciﬁcity for the path-
ophysiological process of plaque rupture, the results could still be to
a degree confounded by the differences in cell composition
between stable and ruptured lesions. Indeed, genes that would be
correlated with the quantity of macrophages present in a lesion
(for example inﬂammatory mediators, matrix metalloproteinases,
pro-apoptotic factors) have been consistently reported as differ-
entially expressed in such studies of whole stable and ruptured
plaques [4e10]. For example, Puig et al. identiﬁed a gene expression
Fig. 4. Immunostained parafﬁn sections of a representative stable atheromatous pla-
que with a thick ﬁbrous cap. Corresponding negative controls stained with haema-
toxylin, smooth muscle cells labelled by smooth muscle actin, macrophages labelled by
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expression proﬁle of laser microdissected macrophages from
a single plaque [10]. No previous study has compared laser
microdissected macrophages from stable and unstable plaques.
However, a degree of overlap between our results and those of
previous studies of whole ruptured and stable plaques provides
external validation for our approach. For example, Papaspyridonos
and colleagues’ study [6] of ruptured versus stable regions of
carotid plaques identiﬁed 170 differentially expressed genes, of
which 33were also identiﬁed in the present study; and other genes
that were highly differentially expressed in our study (for example
myeloid-related protein 14 and heme-oxygenase 1) have also been
identiﬁed by previous reports [7,21]. Dahl and colleagues compared
gene expression in whole plaques from symptomatic and asymp-
tomatic stroke patients, without further radiological or histological
classiﬁcation [9]. Among 136 differentially expressed genes, they
found FABP4 and leptin to be upregulated among symptomatic
patients. Our results add to those previous ﬁndings by incorpo-
rating analyses that demonstrate the importance of the adipocy-
tokine signaling pathway of which these genes are members, and
by demonstrating the cellular origin of the increased plaque levels
of FABP4 and leptin.
Fatty-acid binding-protein 4 (FABP4 or adipocyte/macrophage
fatty-acid binding-protein) was the genemost strongly upregulated
in ruptured plaques in our microarray experiment. FABP4 is
a member of the lipid chaperone family. It is expressed in adipo-
cytes, macrophages and dendritic cells. In the macrophage, FABP4
attenuates cholesterol efﬂux via its inhibitory effect on the perox-
isome proliferator-activated receptor gamma (PPARG) e liver X
receptor-alpha (LXRa) e ATP binding cassette A1 (ABCA1) pathway
[22]. It also regulates inﬂammatory responses via the inhibitor of
kappa-B kinase (IKK)/JNK pathway [22]. FABP4 is the obligatory
mediator coupling lipid-induced toxicity to endoplasmic reticulum
(ER) stress; macrophages are particularly vulnerable to ER stress-
associated apoptosis, especially in environments of high lipid
exposure such as in the atherosclerotic plaque [23,24]. FABP4 plays
a mechanistic role in ER stress through its regulation of fatty acid
synthase (Fasn) and steaoryl CoA desaturase (SCD) via inhibition of
the LXRa nuclear receptor [25]. Mice that are double knockout for
Apolipoprotein E (APOE) and FABP4 are protected from athero-
sclerosis compared to the APOE knockout alone [26]; bone marrow
transplantation studies have shown that this atheroprotective
effect is mainly due to the absence of FABP4 in macrophages [26].
Macrophages from FABP4 knockout animals produce less pro-
inﬂammatory cytokines [22]. In healthy volunteers, increased
circulating FABP4 and Leptin have been recently shown to be
independently associated with increased vascular inﬂammation
measured using ﬂuorodeoxyglucose positron emission tomography
(FDG-PET) [27]. A genetic polymorphism in the FABP4 promoter
region results in diminished FABP4 expression in adipose tissue,
and has been associated with reduced risk of diabetes and cardio-
vascular disease in man [28]. Chemical inhibition of FABP4 using
the small molecule BMS309403 in the APOE knockout mouse
markedly reduced atheroma, and in particular macrophage foam
cell formation [29]. Recent studies in humans found that both high
local FABP4 expression in whole plaques and circulating plasma
levels of FABP4, are associated with vulnerable plaque phenotypes,
plaque-related symptoms, and future adverse clinical cardiovas-
cular events [30,31]. Our cell-speciﬁc data complements these
other observations, and highlights the potential of FABP4 as
a biomarker or therapeutic target in plaque instability.CD68. Leptin and FABP4 immunostaining correlates with the CD68 immunostaining for
macrophages.
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cytes and plays a role in satiety signaling. Recent studies have
demonstrated that leptin has several other actions: it is produced
during inﬂammation, and can modulate the innate and adaptive
immune responses [32]. A variety of potential actions of leptin in
the pathogenesis of atherosclerosis have been proposed - leptin
promotes endothelial dysfunction, smooth muscle cell prolifera-
tion, platelet aggregation and thrombosis, the production of
inﬂammatory cytokines and the calciﬁcation of vascular smooth
muscle cells. The role of leptin in determining cardiovascular risk is
complex. Hyperleptinaemia is an independent risk factor for
coronary artery disease and acute myocardial infarction [32,33]. By
contrast, however, leptin demonstrates acute vasodilatory effects
via endothelial cell dependent and independent mechanisms,
which are in contradiction to the pro-inﬂammatory, thrombogenic,
and atherogenic effects seen in other studies [34]. These observa-
tions may be explained by the chronic effects of leptin on the
endothelium, by the uncoupling of eNOS with excessive oxidative
stress and depletion of NO leading to a disruption of vascular
homeostasis and signiﬁcant endothelial dysfunction [33e35]. An
uncommon polymorphism in the leptin gene has been associated
with carotid intima-medial thickness, a marker of atherosclerosis,
in man [36].
Leptin was clearly expressed in our macrophage-rich areas, and
our analyses of publicly available macrophage gene expression data
conﬁrmed that others had also observed leptin to be expressed in
macrophages. Leptin down-regulates the expression of PPARG in
macrophages in vitro, an effect it has in common with FABP4 [37],
and it acts as a potent macrophage chemoattractant. Leptin has
effects on macrophage lipid accumulation that are of potential
importance in atherosclerosis: macrophages treated with leptin
form cytoplasmic lipid bodies and synthesize the inﬂammatory
eicosanoid leukotriene B4 [38]. Macrophages frommice deﬁcient in
leptin (ob/ob) have a reduced capacity to accumulate cholesterol
compared with wild type cells [39]. Macrophages in human
atherosclerotic plaques also express the leptin receptor [32].
Although a number of previous studies have investigated the
consequences of the exogenous application of leptin to macro-
phages, and the local paracrine and ‘vasocrine’ effects of leptin from
perivascular adipose tissue has been hypothesised and studied
[32,33,35], none has explored the potential importance of auto-
crine/paracrine signaling by macrophage-derived leptin. Our
results suggest such signaling may promote intracellular lipid
accumulation and inﬂammatory mediator production that predis-
pose to plaque instability. The differences we observed in the
expression of downstream signaling molecules in the leptin
pathway such as RXR-alpha, STAT3, IRS, and Akt, reinforce the
suggestion that this pathway is activated when plaques become
unstable.
Certain limitations of this study merit comment. The laser
micro-dissection approach we describe is technically challenging,
and was therefore performed on only a limited number of samples.
This limits the precisionwith which we can quantify the expression
differences we have observed. Although our comparisons with
publicly available expression proﬁles from macrophages clearly
indicate the largely macrophage origin of our RNA, we cannot
exclude a degree of contamination from other cell types intimately
associated with the macrophage in the atheromatous plaque. Nor
can our approach take account of heterogeneity within the
macrophage population in any plaque studied. Since plaques are
known to progress by a repeated process of rupture (mainly
asymptomatic) and healing, and some of the ruptured samples
were collected up to three months after a clinical stroke or TIA, we
also cannot entirely rule out an involvement of certain of the genes
we have identiﬁed in the healing rather than the rupture process(although this seems unlikely to be the case for FABP4 and leptin).
Future studies will be necessary to characterize the downstream
consequences of the up-regulation of FABP4 and leptin expression
in unstable plaque macrophages. Also, systematic investigation of
differentially expressed genes in other KEGG pathways we identi-
ﬁed would be of substantial interest.
In conclusion, we have demonstrated signiﬁcant differences
between gene expression patterns in macrophages from stable and
ruptured plaques. Our results provide further support that thera-
peutic efforts to down-regulate the PPAR/Adipocytokine signaling
pathway involving FABP4 and leptin in plaquemacrophages may be
a useful plaque stabilization strategy.
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